VEDCO Launches The First FDAApproved Generic Carorofen Caplets

May 16, 2005 -- Vedco Inc., is pleased to announce the immediate availability of Novox Caplets (carprofen), indicated for the relief of pain and inflammation associated with osteoarthritis in dogs. Novox Caplets are the first FDA-approved generic carprofen caplets in the United States Animal Health Market.

"Osteoarthritis is a very painful degeneration of the joint and one of the most common ailments afflicting America's dog population today, particularly older and large breed dogs," said Craig Campbell, Vedco General Manager. "Unfortunately, many of these dogs are not being treated, either due to the dog-owner not recognizing the symptoms and/or the cost that the dog-owner incurs as a result of treatment. Now, with the availability of Novox Caplets, veterinarians will be able to offer effective pain relief for their dog-owning clients at a price that will make it much more affordable for dog-owners."

Novox is a non-steroidal anti-inflammatory drug (NSAID), available by prescription only through a licensed veterinarian.

Novox Caplets are available in three strengths; 25mg, 75mg and 100mg. Each of these three strengths are packaged in 60 count and 180 count bottles.

For more information about Novox Caplets contact your authorized Vedco distributor or contact Vedco direct at (888) 708-3326 or visit the Vedco web site at www.vedco.com or the Novox Caplet web site at www.novoxcaplets.com.

About Us: Vedco Inc
5503 Corporate Dr
Saint Joseph, Mo 64507

Contact Info: Contact: Your authorized Vedco Distributor or Vedco direct at (888) 708-3326




VEDCO Launches The First FDAApproved Generic Carorofen Caplets



***Note This page is an Archieve of Publicly released information either through our company or another Press Release organization. We do not "fact check", "Support", nor "Dispute" any of the information provided to us. We are a distribution point and Historical press release research and search service. This information only represents the fact that at one point in time the release was distributed to 1000's of publications both online and off. PRNewsNow will not take sides in any personal or commercial disputes you have with the writer of this press release. We will defend its right to exist blindly and without regards to its political, commercial or personal implications.***